Harvard Bioscience Outlines Post-Refi Strategy, Organoid Growth Focus

Company highlights new leadership, debt refinancing, and plans to expand organoid and bioproduction offerings

Mar. 22, 2026 at 11:06am

Got story updates? Submit your updates here. ›

Harvard Bioscience (NASDAQ:HBIO) executives used a recent KeyBanc Capital Markets discussion to outline the company's strategic focus following leadership changes and a debt refinancing completed late last year. CEO John Duke and CFO Mark Frost discussed portfolio management, growth opportunities in organoids and bioproduction, and margin and cost initiatives.

Why it matters

Harvard Bioscience is a major player in the life sciences research tools market, providing a diverse range of scientific equipment used by academic, biopharmaceutical and government labs worldwide. The company's strategic shift under new leadership and its focus on high-growth areas like organoids and bioproduction could position it for stronger performance in the years ahead.

The details

Duke said the company will continue evaluating its portfolio, focusing on areas with significant organic and potential inorganic growth, such as organoids and the BTX product line used in bioprocessing. He highlighted the company's Mesh MEA (microelectrode array) system for organoid research, which he said provides a 'true-to-life signal' compared to 2D surfaces. Duke said the company is seeing positive uptake, expanding beyond research institutes to pharmaceutical customers. Frost outlined a debt refinancing that could help deleverage the business and generate additional cash flow. Management also discussed margin improvement initiatives, including consolidating manufacturing and shifting certain products to 'centers of excellence'.

  • In July 2025, John Duke became CEO of Harvard Bioscience.
  • Last week, Mark Frost joined as the company's permanent CFO.
  • The company completed a debt refinancing late last year.

The players

John Duke

CEO of Harvard Bioscience, with over a decade of experience in the life sciences industry, including time at Corning's life science business.

Mark Frost

CFO of Harvard Bioscience, who joined the company last week and has prior roles across GE businesses and as CFO in biotech, CDMO, med tech, and diagnostic imaging.

Harvard Bioscience, Inc.

A developer, manufacturer and distributor of life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

Harvard Bioscience's strategic shift under new leadership, with a focus on high-growth areas like organoids and bioproduction, coupled with its debt refinancing and margin improvement initiatives, could position the company for stronger performance in the life sciences research tools market.